Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

7(87.5%)

Phase 2

1(12.5%)

8Total

N/A(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07573865Not ApplicableNot Yet Recruiting

tDCS and Bi-manual Training in Cerebral Palsy

Role: collaborator

NCT02864732Not ApplicableCompleted

Stabilization Exercises Alone vs Stabilization Exercises Plus Neuromuscular Electrical Stimulation in People With Chronic Low Back Pain

Role: collaborator

NCT04347681Phase 2Completed

Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

Role: lead

NCT04646577Not ApplicableUnknown

The Effect of tDCS Combined With Functional Task Training on Motor Recovery in Stroke Patients

Role: lead

NCT03943069Not ApplicableUnknown

Thoracoscopic Bullectomy Versus Thoracoscopic Bullectomy With Pleurodesis in Primary Spontaneous Pneumothorax

Role: collaborator

NCT04377802Not ApplicableUnknown

Safe Return to Regular Clinical Operation After COVID-19 Pandemic

Role: lead

NCT03810937Not ApplicableUnknown

Optimal Head and Neck Position for Videolaryngoscopy

Role: lead

NCT03813043Not ApplicableUnknown

The 90% Effective Sedation Dose Of Midazolam

Role: lead

All 8 trials loaded